HomeBest Practice
Best Practice
Advancing Polio Eradication with Novel Oral Polio Vaccine type 2 (nOPV2)
Introduction: The development of the novel oral polio vaccine type 2 (nOPV2) began in 2011, and after a decade of rigorous research and testing, it...
Reflecting on Potential Pandemic Threats
Learning from our most recent pandemic experience (COVID-19) must provide us with help to handle much better future pandemic threats. First and subsequent responders...
Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, September 2024
This report summarizes SAGE discussions, conclusions, and recommendations. All recommendations were made using evidence-based methods. The SAGE meeting in March 2024 celebrated the achievements of...
Pneumococcal Conjugated Vaccines (PCVs) Short Schemes: the UK experience
In 2006, the UK introduced the 7-valent PCV (PCV7) into the infant immunization program with a 2+1 schedule, alongside a 12-month catch-up for all...
Novel meningococcal pentavalent vaccine (Men5CV) for Africa
Meningitis is one of the leading causes of mortality and morbidity, especially in the meningitis belt of sub-Saharan Africa, with a recorded disease burden...
Simplified Rabies Vaccine Schedules
Rabies is a viral zoonotic disease responsible for an estimated 59,000 human deaths and over 3.7 million disability-adjusted life years (DALYs) lost every year. As...
Hepatitis A Vaccine: The case of a 1-dose schedule in children
Hepatitis A virus (HAV) causes inflammatory liver disease that may progress to fulminant liver failure. HAV is transmitted primarily via the fecal/oral route through...
One dose of Human Papilloma Virus vaccine as a global strategy to prevent cervical cancer
Even though Human Papilloma Virus (HPV) causes cancer in several epithelia, the priority purpose of HPV massive immunization is the prevention of cervical cancer...
